AusCann (ASX: AC8) has announced a research support programme for investigator-led research studies, utilising their $16.8 million cash balance to grow the companies IP.
The announcement states the launching of their research web page which calls for expressions of interest for relevant studies, however as at publication no such page can be found.
This support programme comes alongside the established of a Clinical Advisory Board led my Dr Marc Russo, which aims to finalise the companies advanced data management and analytics platform, designed to meet the needs of Australian medicinal cannabis prescribers of AusCann’s products.
Currently, AusCann only has one product on the market – a 1:1 CBD:THC low-dose hard-shelled capsule. However, their recent quarterly report showed only $5,000 in revenue for sales.